ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
59 announcements with these filters
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Alembic Pharmaceuticals submitted a certificate confirming the utilization of proceeds from Commercial Papers for the quarter ended September 30, 2026, as required by SEBI regulations.
DSP Trustee Private Limited and associated funds sold 1,36,574 equity shares of Alembic Pharmaceuticals Limited. This open market transaction reduced their total stake to 2.97%.
Alembic Pharmaceuticals has redeemed commercial papers worth ₹200 Crore on their maturity date, 28th September 2026. This confirms the company's full repayment of the debt obligation.
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
Alembic Pharmaceuticals Limited has appointed Mr. Chirag Shukla as the Company Secretary and Compliance Officer (Key Managerial Personnel), effective 20th August, 2026.
Alembic Pharmaceuticals' Company Secretary and Compliance Officer, Ms. Manisha Saraf, has resigned from her position effective August 10, 2026.
Q1FY27 revenue grew 26% to INR 2,150 Cr. Strategy focuses on US Generics volume growth, India Specialty therapeutic scale-up, and managing margin dilution from US branded investments.
Alembic Pharmaceuticals held its 16th Annual General Meeting on August 5, 2026. The meeting covered adoption of financial statements, dividend declaration, and director appointments.
Alembic Pharmaceuticals reported Q1 FY27 revenue of Rs. 2,150 Crore, a 26% YoY increase. Net profit rose 12% to Rs. 173 Crore during the period.
Alembic Pharmaceuticals reported a 26% revenue increase to ₹2,150 Crore for Q1 FY27. Profit After Tax grew 12% to ₹173 Crore, driven by strong US growth.
Alembic Pharma delivered strong Q1 FY27 results with 26% revenue growth, driven by a 49% surge in US formulations. Strategy focuses on specialty US branded expansion and peptide development.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,150 Cr (+25.7% YoY) and net profit of ₹173.1 Cr (+12.1% YoY) for Q1 FY27.
Alembic Pharmaceuticals Limited received USFDA final approval for Prucalopride Tablets (1 mg and 2 mg). The product addresses a US$ 100 million market for chronic idiopathic constipation.